Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411621 | 0.83 | MAP3K14 (0.34) | MAOBNPC1RAB9A | |
| SCHEMBL512386 | 0.77 | KDM4E (0.31) | ABCG2NPC1RAB9A | |
| SCHEMBL3047514 | 0.69 | USP2 (0.35) | — | |
| SCHEMBL17289104 | 0.67 | AHR (0.30) | — | |
| SCHEMBL717364 | 0.67 | CYP3A4 (0.35) | MAOBABCG2NPC1RAB9ACYP3A4 | |
| SCHEMBL409478 | 0.65 | MAOB (0.56) | MAOBABCG2NPC1RAB9ACYP3A4 | |
| SCHEMBL29826933 | 0.65 | MAOB (0.56) | MAOBABCG2NPC1RAB9ACYP3A4 | |
| SCHEMBL5887483 | 0.64 | NPC1 (0.43) | MAOBNPC1RAB9A | |
| SCHEMBL349205 | 0.63 | — | — | |
| SCHEMBL30787730 | 0.63 | AHR (0.53) | MAOBABCG2NPC1RAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | MAOB 2884/4885ABCG2 2354/4885NPC1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.